Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer
Status:
Completed
Trial end date:
2001-01-01
Target enrollment:
Participant gender:
Summary
An open, dose-ranging, multiple dose, multi-centre study in patients with Stage I-III or
Stage IV gastric cancer. Twelve patients in each of 5 treatment groups were to receive three
injections at weeks 0, 2 and 6 with provision for a single booster injection in an extension
study period.